Alemtuzumab long-term immunologic effect
Treg suppressor function increases up to 24 months
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received September 14, 2015
- Accepted in final form October 30, 2015
- First Published January 21, 2016.
Author Disclosures
- Stefania De Mercanti, MD*,
- Simona Rolla, BS, PhD*,
- Angele Cucci, BS, PhD,
- Valentina Bardina, BS,
- Eleonora Cocco, MD,
- Anton Vladic, MD, PhD,
- Silva Soldo-Butkovic, MD, PhD,
- Mario Habek, MD, PhD,
- Ivan Adamec, MD, PhD,
- Dana Horakova, MD, PhD,
- Pietro Annovazzi, MD,
- Francesco Novelli, BS, PhD‡,
- Luca Durelli, MD‡ and
- Marinella Clerico, MD, PhD‡
- Stefania De Mercanti, MD*,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Simona Rolla, BS, PhD*,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Angele Cucci, BS, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Valentina Bardina, BS,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Eleonora Cocco, MD,
Dr Cocco serves on scientific advisory boards from Bayer, Biogen, Merck, Novartis, Sanofi-Genzyme and Teva
NONE
Dr Cocco has received no profit travel supports for congress partecipation by Biogen, Merck, Bayer, Novartis, Genzyme, TEVA
NONE
NONE
NONE
NONE
NONE
Dr Cocco has received speaker fees for educational activities (no profit) with Biogen, Merck, Bayer, Novartis Genzyme, TEVA and Almirall.
NONE
NONE
NONE
NONE
NONE
2013, 2014, 2015 founding by Fondazione Banco di Sardegna Founded by Italian Multiple sclerosis foundation 2012/R3
NONE
NONE
NONE
NONE
NONE
NONE
- Anton Vladic, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Silva Soldo-Butkovic, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Mario Habek, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ivan Adamec, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Dana Horakova, MD, PhD,
NONE
NONE
Dr. Horakova received compensation for travel, speaker honoraria and consultant fees from Biogen Idec, Novartis, Merck, Bayer Shering, and Teva
An associate editor in BMC neurology
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Support for research activities from Biogen Idec.
Supported by Czech Ministries of Education and Health [NT13237-4/2012, PRVOUK-P26/LF1/4].
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Pietro Annovazzi, MD,
Dr. P. Annovazzi received honoraria for serving in the scientific advisory boards of Merck Serono, Novartis, Biogen and Genzyme
NONE
Dr. P. Annovazzi received speaker honoraria from Biogen, Genzyme, Novartis and TEVA
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Francesco Novelli, BS, PhD‡,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Luca Durelli, MD‡ and
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Marinella Clerico, MD, PhD‡
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Division of Neurology (S.D.M., S.R., A.C., L.D., M.C.) and the Department of Clinical and Biological Sciences (S.D.M., A.C., L.D., M.C.), University of Torino, San Luigi Gonzaga University Hospital, Orbassano; Center for Experimental Research and Medical Studies (CERMS) (S.R., V.B., F.N.), Azienda Ospedaliera Città della Salute e della Scienza di Torino; Department of Molecular Biotechnology and Health Sciences (V.B., F.N.), Università degli Studi di Torino; Multiple Sclerosis Center (E.C.), Department of Public Health, Clinical and Molecular Medicine, University of Cagliari, Italy; Department of Neurology (A.V., S.S.-B.), Clinical Hospital Sveti Duh Zagreb; Medical Faculty University (A.V., S.S.-B.), J.J. Strossmayer Osijek; Department of Neurology (M.H., I.A.), Referral Center for Demyelinating Diseases of the Central Nervous System, University Hospital Center Zagreb, Croatia; Department of Neurology and Center of Clinical Neuroscience (D.H.), Charles University in Prague, First Faculty of Medicine and General University Hospital, Czech Republic; and Multiple Sclerosis Study Center (P.A.), AO S. Antonio Abate, Gallarate (VA), Italy.
- Correspondence to Dr. Durelli: luca.durelli{at}unito.it
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.